<DOC>
	<DOCNO>NCT01139580</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness treatment psoriasis scalp body .</brief_summary>
	<brief_title>The Purpose This Study Demonstrate Safety Effectiveness Calcipotriene Foam Subjects With Scalp Body Psoriasis</brief_title>
	<detailed_description>The study subject must moderate psoriasis body scalp ISGA 3 baseline . In addition , subject must evaluable target lesion least 2 cm² body score 2 3 erythema , scale plaque . All subject apply Calcipotriene Foam , 0.005 % vehicle foam topically twice day ( pm ) psoriatic lesion body scalp . Study visit occur baseline ( day 1 ) week 1 , 2 , 4 , 8 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Capable understand willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocolspecific procedure perform . Male female subject least 12 year old good general health . Able complete study comply study instruction . Moderate plaquetype psoriasis body ( exclude scalp face ) define : Plaquetype psoriasis involve 3 % 10 % total body surface area ( BSA ) . An Investigator 's Static Global Assessment ( ISGA ) score 3 Baseline . Identification target lesion ( &gt; 2 cm² ) trunk extremity score 2 3 ( 05 scale ) erythema , scale plaque thickness . Lesions palms/soles , knee , elbow , intertriginous area use target lesion site . Involvement least 10 % total scalp surface area clinical sign ( erythema , thickness , scaliness ) rat moderate ( 3 ) base ISGA . Negative urine pregnancy test female childbearing potential . • Sexually active female childbearing potential participating study must agree use medically acceptable method contraception receive protocolassigned product . A woman childbearing potential define one biologically capable become pregnant ; include perimenopausal woman few 2 year last menses . Any subject participate previous calcipotriene foam clinical . Female pregnant , try become pregnant , breastfeed . Known allergy adverse reaction calcipotriene vitamin D analog ; component investigational formulation . History hypercalcemia vitamin D toxicity . Other serious skin disorder chronic medical condition wellcontrolled . Use nonbiologic systemic antipsoriatic therapy ( eg , corticosteroid , psoralen combine exposure ultraviolet light A [ PUVA ] , ultraviolet light B [ UVB ] , retinoids , methotrexate , cyclosporine , immunosuppressive agent ) within 4 week prior enrollment . Systemic treatment biological therapy ( market market ) possible effect psoriasis within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever longer ) experimental product prior randomization . Use topical therapy know beneficial effect psoriasis , include limited corticosteroid , retinoids , Vitamin D derivative , coal tar , anthralin , within 2 week prior enrollment . Systemic medication medical condition know affect psoriasis ( eg , lithium , beta adrenergic blocker ) within 4 week prior enrollment . Use investigational product within 4 week prior enrollment , currently participate another clinical trial , plan receive investigational product study . Current drug alcohol abuse ( drug screening require ) . Has history immunocompromizing disease . Any condition , judgment investigator , would put subject unacceptable risk participation study . Employees investigator ; study center ; Stiefel , GSK company involve study ; immediate family member ( eg , partner , offspring , parent , sibling sibling 's offspring ) employee involve study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Psoriasis</keyword>
</DOC>